Post-earnings recap
Reported
Tue, Aug 7, 2018
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
Despite missing EPS expectations, TG Therapeutics' stock rose by 2.10% following the earnings report. This increase may reflect investor confidence in the company's ongoing development efforts and the potential of its clinical pipeline. The lack of revenue data and guidance suggests uncertainty, but the positive stock reaction indicates some optimism among investors.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.59 | N/A | -7.33% |
| Revenue | N/A | N/A | N/A |
Management expressed cautious optimism about the company's pipeline and future developments. They reiterated their commitment to advancing their clinical programs.
Management highlighted ongoing development efforts and future potential.
They emphasized the importance of upcoming clinical trials.
There was a focus on maintaining operational efficiency.